NICE draft guidance rejects Celgene drug for MM

11 November 2016

The National Institute for Health and Care Excellence (NICE) has today issued draft guidance rejecting use on the National Health Service of a treatment for multiple myeloma.

The cost effectiveness watchdog for England and Wales says it is not recommending US biotech firm Celgene’s (Nasdaq: CELG) Revlimid (lenalidomide) for people with multiple myelomawho have had one prior treatment with bortezomib, pointing out that it has already recommends lenalidomide as third line treatment for multiple myeloma.

Lenalidomide, for this appraisal, is used to treat people who have had one prior treatment with bortezomib and can’t have a stem cell transplant. Compared with other treatments, such as melphalan (a cytotoxic chemotherapy), the NICE appraisal committee concluded that lenalidomide, to treat multiple myeloma for this patient population, ie, earlier in the treatment pathway, is not a cost effective use of NHS resources.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK